

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/785,374
				Filing Date	February 24, 2004
				First Named Inventor	Summar et al.
				Art Unit	1638
				Examiner Name	D. Johannsen
(Use as many sheets as necessary)				Attorney Docket Number	1242/58 CIP
Sheet	1	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Aschner, J. L., "New Therapies for Pulmonary Hypertension in Neonates and Children," <i>Pediatr. Pulmonol. Suppl.</i> , Vol. 26, pgs. 132-135 (2004).	
	2	Blum et al., "Oral L-arginine in Patients with Coronary Artery Disease on Medical Management," <i>Circulation</i> , Vol. 101, pgs. 2160-2164 (May 9, 2000).	
	3	Chin-Dusting et al., "Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure," <i>J. Am. Coll. Cardiol.</i> , Vol. 27, pgs. 1207-1213 (1996).	
	4	Feng et al., "Effects of L-arginine on endothelial and cardiac function in rats with heart failure," <i>Eur. J. Pharmacol.</i> , Vol. 376, pgs. 37-44 (July 2, 1999).	
	5	Hladunewich et al., "Effect of L-arginine therapy on the glomerular injury of preeclampsia: a randomized controlled trial," <i>Obstet. Gynecol.</i> , Vol. 107, pgs. 886-895 (2006).	
	6	Laursen et al., "Hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy is unaltered by long-term oral L-arginine administration," <i>Vascul. Pharmacol.</i> , Vol. 49, pgs. 71-76 (2008).	
	7	Lorente et al., "Modulation of systemic hemodynamics by exogenous L-arginine in normal and bacteremic sheep," <i>Crit. Care Med.</i> , Vol. 27, pgs. 2474-2479 (1999).	
	8	Miller et al., "Effects of an acute dose of L-arginine during coronary angiography in patients with chronic renal failure: a randomized, parallel, double-blind clinical trial," <i>Am. J. Nephrol.</i> , Vol. 23, pgs. 91-95 (2003).	
	9	Morris et al., "Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease," <i>J. Pediatr. Hematol. Oncol.</i> , Vol. 25, pgs. 629-634 (2003).	
	10	Paulus et al., "Myocardial contractile effects of L-arginine in the human allograft," <i>J. Am. Coll. Cardiol.</i> , Vol. 29, pgs. 1332-1338 (1997).	
	11	Romero et al., "Therapeutic use of citrulline in cardiovascular disease," <i>Cardiovasc. Drug Rev.</i> , Vol. 24, pgs. 275-290 (2006).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/785,374
			Filing Date	February 24, 2004
			First Named Inventor	Summar et al.
			Art Unit	1638
			Examiner Name	D. Johannsen
(Use as many sheets as necessary)			Attorney Docket Number	1242/58 CIP
Sheet	2	of	2	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	Schulman et al., "L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial," JAMA, Vol. 295, pgs. 58-64 (January 4, 2006).	
	13	Simko et al., "L-arginine fails to protect against myocardial remodelling in L-NAME-induced hypertension," Eur. J. Clin. Invest, Vol. 35, pgs. 362-368 (2005).	
	14	Stier et al., "Dietary arginine fails to protect against cerebrovascular damage in stroke-prone hypertensive rats," Brain Res., Vol. 549, pgs. 354-356 (May 24, 1991).	
	15	Surdacki et al., "Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension," Wien. Klin. Wochenschr., Vol. 106, pgs. 521-526 (1994).	
	16	Wilson et al., "L-arginine supplementation in peripheral arterial disease: no benefit and possible harm," Circulation, Vol. 116, pgs. 188-195 (July 10, 2007).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.